Marcelo Fernández

Marcelo Fernández

Auto-generated profile, based on publicly available information

Marcelo Fernández

Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
XCXimena Camacho
Ximena Camacho
CPCarolina Perroni
Carolina Perroni
CMCamila Maria Longo Machado
Camila Maria Longo Machado
CCCamila de Godoi Carneiro
Camila de Godoi Carneiro
MJMara de Souza Junqueira
Mara de Souza Junqueira
JGJuan Pablo Gambini
Juan Pablo Gambini
Background: Multiple Myeloma (MM) is a malignant hematologic disorder and the second most common blood cancer. Interleukin-6 (IL-6) has been identified as a crucial factor for the proliferation and survival of MM cells and the overexpression of IL-6 receptor is being studied as a molecular target for therapeutic and diagnostic use in myelomas and other comorbidities. Tocilizumab is a humanized monoclonal antibody that binds IL-6R. Objective: We aim to label and evaluate Fab(Tocilizumab) with 99mTechnetium or Cy7 as potential MM imaging agents. Methods: IL-6R distribution was analyzed by Laser Confocal Microscopy (LCM) in MM cell lines. Fab(Tocilizumab) was produced by the digestion of Tocilizumab with papain for 24h at 37°C, derivatized with NHS-HYNIC-Tfa and radiolabeled with 99mTc. Radiochemical stability and in vitro cell assays were evaluated. Biodistribution and SPECT/CT were performed. Also, Fab(Tocilizumab) was labeled with Cy7 for in vivo fluorescence imaging up to 72h. Results: LCM analysis demonstrates IL-6R distribution on MM cell lines. Incubation with papain resulted in complete digestion of Tocilizumab and exhibited a good purity and homogeneity. Radiolabeling with 99mTc via NHS-HYNIC-Tfa was found to be fast, easy, reproducible and stable, revealing high radiochemical purity and without interfering with IL-6R recognition. Biodistribution and SPECT/CT studies showed a quick blood clearance and significant kidney and MM engrafted tumor uptake. Cy7-Fab(Tocilizumab) fluorescent imaging allowed MM1S tumor identification up to 72h p.i. Conclusion: These new molecular imaging agents could potentially be used in the clinical setting for staging and follow-up of MM through radioactive whole-body IL-6R expression visualization in vivo. The fluorescent version could be used for tissue sample evaluation and to guide surgical excision, if necessary.

10 March 2026 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
XCXimena Camacho
Ximena Camacho
MCMirel Cabrera
Mirel Cabrera
CPCarolina Perroni
Carolina Perroni
MTMarcos Tassano
Marcos Tassano
MFMarcelo Fernández
Marcelo Fernández
PCPablo Cabral
Pablo Cabral
Introduction: Multiple Myeloma (MM) is a haematological malignancy in which Interleukin-6 (IL-6) plays a crucial role in its growth and spread. The monoclonal antibody Tocilizumab binds strongly to IL-6 receptors, inhibiting their function. Our aim is to evaluate the potential of [177Lu]Lu-labeled Toclilzumab as a theranostic agent for MM. Methods: Tocilizumab was derivatised with DOTA-NHS ester and radiolabeled with [177Lu]Lu. The stability of the radiochemical compound was evaluated, and in vitro binding and immunoreactive fraction assays were performed. Biodistribution was assessed at 24 and 48 h post-injection (n = 5) in normal and MM-bearing BALB/c nude mice. Results: [177Lu]Lu-DOTA-Tocilizumab remained stable in all tested solutions. Epitope recognition was confirmed by cell-binding studies, and an immunoreactive fraction of 83.7% was observed. In vivo biodistribution studies revealed high tumor uptake over time, with tumor-to-muscle ratios of 11.66 ± 3.81 and 9.54 ± 1.75 at 24 and 48 h, respectively. Discussion: This study focused on the synthesis and characterisation of a new radiolabeled theranostic agent against IL6R, [177Lu]Lu-DOTA-Tocilizumab. This agent demonstrated high radiochemical stability and strong binding to IL-6R in the MM cell line. Biodistribution studies indicated selective retention of the agent in tumor tissue, highlighting its potential for targeted imaging and therapy in IL-6R-positive cancers and paving the way for future research into its application in related diseases. Conclusions: [177Lu]Lu-DOTA-Tocilizumab represents a potential theranostic agent for MM. Therefore, we expect this agent to open the way to new diagnostic and therapeutic strategies for this devastating disease.

1 November 2024 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
XCXimena Camacho
Ximena Camacho
CPCarolina Perroni
Carolina Perroni
LALucía Alfaya
Lucía Alfaya
MCMirel Cabrera
Mirel Cabrera
MTMarcos Tassano
Marcos Tassano
JGJuan Pablo Gambini
Juan Pablo Gambini
Background: Angiogenesis is a process that many tumors depend on for growth, development, and metastasis. Vascular endothelial growth factor (VEGF) is one of the major players in tumor angiogenesis in several tumor types, including melanoma. VEGF inhibition is achieved by bevacizumab, a humanized monoclonal antibody that binds with high affinity to VEGF and prevents its function. In order to successfully enable in vivo VEGF expression imaging in a murine melanoma model, we previously labeled bevacizumab with [99mTc]Tc. We observed that this was feasible, but it had prolonged blood circulation and delayed tumor uptake. Objective: The aim of this study was to develop a radiolabeled Fab bevacizumab fragment, [99mTc]Tc-HYNICFab( bevacizumab), for non-invasive in vivo VEGF expression molecular imaging. Methods: Flow cytometry was used to examine VEGF presence in the murine melanoma cell line (B16-F10). Bevacizumab was digested with papain for six hours at 37°C to produce Fab(bevacizumab), which was then conjugated to NHS-HYNIC-Tfa for radiolabeling with [99mTc]Tc. Stability and binding affinity assays were also evaluated. Biodistribution and single photon emission computed tomography/computed tomography (SPECT/CT) were performed at 1, 3, and 6 h (n = 4) after injection of [99mTc]Tc-HYNIC-Fab(Bevacizumab) in normal and B16-F10 tumor-bearing C57Bl/6J mice. Results: Using flow cytometry, it was shown that the B16-F10 murine melanoma cell line has intracellular VEGF expression. Papain incubation resulted in the complete digestion of bevacizumab with good purity and homogeneity. The radiolabeling yield of [99mTc]Tc-HYNIC-Fab(bevacizumab) was 85.00 ± 6.06%, with a specific activity of 291.87 ± 18.84 MBq/mg (n=3), showing in vitro stability. Binding assays demonstrated significant intracellular in vitro VEGF expression. Fast blood clearance and high kidney and tumor uptake were observed in biodistribution and SPECT/CT studies. Conclusions: We present the development and evaluation of [99mTc]Tc-HYNIC-Fab(bevacizumab), a novel molecular VEGF expression imaging agent that may be used for precision medicine in melanoma and potentially in other VEGF-expressing tumors.

1 June 2017 in SALUD MILITAR
Verified
Journal Article
Open access
PDF file
CPCarolina Perroni
Carolina Perroni
XCXimena Camacho
Ximena Camacho
MGMaría Fernanda García
María Fernanda García
MFMarcelo Fernández
Marcelo Fernández
HCHugo Cerecetto
Hugo Cerecetto
PCPablo Cabral
Pablo Cabral
El factor de crecimiento endotelial vascular (VEGF), es un factor clave en la angiogénesis tumoral de muchos tipos de tumores, incluyendo el Linfoma No Hodgkin (LNH). El objetivo del presente trabajo es la radiomarcación de los fragmentos de unión al antígeno (Fab) del 99m anticuerpo monoclonal Bevacizumab con Tc y su evaluación como potencial agente de imagen para LNH. Para lograrlo se analizó la expresión de VEGF mediante citometría de flujo en una línea celular de LNH (Toledo). La fragmentación se realizó empleando papaína y los Fab obtenidos fueron conjugados con NHS-HYNIC-Tfa y 99m radiomarcados con Tc. La pureza radioquímica y la estabilidad fueron ensayadas. Se realizaron estudios de biodistribución tanto en ratones sanos como en portadores de LNH. Se observó que las células Toledo presentaron una elevada expresión de VEGF. El radiomarcaje se realizó de forma rápida, sencilla, reproducible y estable, con purezas radioquímicas >90%. Los estudios de biodistribución revelaron una significativa captación renal y tumoral, indicando que la principal vía de eliminación es renal. De los resultados 99m obtenidos se concluye que el Tc-HYNIC-Fab (Bevacizumab) representa un potencial a agente de imagen de la expresión de VEGF asociada a LNH. Recibido: Agosto 2017 Aceptado: Octubre 2017 Correspondencia: : Laboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay. Mataojo 2055, P.O. 11400, Montevideo, Uruguay. Tel.: (+5982) 5250901/108; Fax: (+5982) 5250895 E-mail de contacto: pcabral@cin.edu.uy

1 January 2012 in SALUD MILITAR
Verified
Journal Article
Open access
PDF file
XCXimena Camacho
Ximena Camacho
VCVictoria Calzada
Victoria Calzada
MFMarcelo Fernández
Marcelo Fernández
María Fernanda GarcíaMaría Fernanda García
María Fernanda García
MMMaría Moreno
María Moreno
APAntonio Pandiella
Antonio Pandiella
La interleucina 6 (IL-6) es una molécula clave en la patogénesis del Mieloma Múltiple (MM). La sobre-expresión de su receptor, IL6R, en las células de MM se puede utilizar como blanco para el desarrollo de potenciales agentes moleculares para su diag-nóstico. El Tocilizumab (Actemra®) es un anticuerpo monoclonal contra IL6R. El objetivo de este trabajo es el desarrollo y evaluación, a través de distintos métodos químicos y biológicos, la marcación de 99mTc-Tocilizumab utilizando dos agente quelantes, Succidinimyl-hidrazinonicotinamida (HYNIC) y tricarbonilo. En primer lugar se derivatizó el Tocilizumab (Roche) con HYNIC y se marcó utilizando 99mTc/tricina/Sn2Cl a temperatura ambiente. La marcación del anticuerpo con [99mTc(CO)3(OH2)3]+ se llevó a cabo incubando 45 min a 37ºC. La pureza radioquímica (PQR) fue evaluada por ITLC-SG y HPLC. Se realizaron estudios in-vitro de unión y competencia con células de MM U266 hasta 120 minutos. Se obtuvieron imágenes fluorescentes y por microscopía de fuerza atómica de las células U266. Se realizaron estudios in-vivo en ratones CD1 normales (n=3). Se observó una PRQ mayor a 90% con ambos quelantes utilizados, siendo estable y sin mostrar transquelación significativa al menos durante 24 hs. La microscopía confocal mostró la capacidad del Tocilizumab-FITC para reconocer IL6R en las células U266. Los experimentos in-vitro de unión y desplazamiento confirman la especificidad de reconocimiento del 99mTc-Tocilizumab por IL6R. Los estudios de biodistribución mostraron absorción hepática y eliminación renal principalmente. De los resultados obtenidos se concluyó que ambos marcados del Tocilizumab con 99mTco4-, vía HYNIC y vía tricarbonilo, podrían ser potenciales agentes de imagen para el diagnóstico de Mieloma Múltiple. Recibido para revisión: Junio 2012.Aceptado para publicación: Agosto 2012. Interleukin-6 (IL-6) is a key molecule in the pathogenesis of multiple myeloma (MM). Over-expression of its receptor, IL6R, in MM cells can be used as a target for the development of potential molecular agents for its diagnosis. Tocilizumab (Actemra®) is a monoclonal antibody against IL6R. The objective of this work is to develop and evaluate, through different chemical and biological methods, the labeling of 99mTc-Tocilizumab using two chelating agents, Succidinimyl-hydrazinonicotinamide (HYNIC) and tricarbonyl. Tocilizumab (Roche) was first derivatized with HYNIC and labeled using 99mTc/tricine/Sn2Cl at room temperature. Antibody labeling with [99mTc(CO)3(OH2)3]+ was carried out by incubating 45 min at 37°C. Radiochemical purity (PQR) was evaluated by ITLC-SG and HPLC. In-vitro binding and competition studies were performed with MM U266 cells for up to 120 min. Fluorescent and atomic force microscopy images of U266 cells were obtained. In-vivo studies were performed in normal CD1 mice (n=3). A PRQ greater than 90% was observed with both chelators used, being stable and showing no significant transchelation for at least 24 hs. Confocal microscopy showed the ability of Tocilizumab-FITC to recognize IL6R in U266 cells. In-vitro binding and displacement experiments confirm the specificity of recognition of 99mTc-Tocilizumab by IL6R. Biodistribution studies showed hepatic absorption and renal elimination mainly. From the results obtained it was concluded that both 99mTco4- labeled Tocilizumab, via HYNIC and via tricarbonyl, could be potential imaging agents for the diagnosis of Multiple Myeloma. Received for review: June 2012.Accepted for publication: August 2012. A interleucina-6 (IL-6) é uma molécula chave na patogênese do mieloma múltiplo (MM). A sobre-expressão de seu receptor, IL6R, em células MM pode ser usada como alvo para o desenvolvimento de potenciais agentes moleculares para diagnóstico. Tocilizumab (Actemra®) é um anticorpo monoclonal contra a IL6R. O objetivo deste trabalho é desenvolver e avaliar, através de diferentes métodos químicos e biológicos, a rotulagem de 99mTc-Tocilizumab usando dois agentes quelantes, Succidinimil-hidrazinonicotinamida (HYNIC) e tricarbonil. Tocilizumab (Roche) foi primeiramente derivatizado com HYNIC e rotulado usando 99mTc/tricine/Sn2Cl à temperatura ambiente. A rotulagem do anticorpo com [99mTc(CO)3(OH2)3]+ foi realizada incubando durante 45 min a 37ºC. A pureza radioquímica (PQR) foi avaliada pela ITLC-SG e HPLC. Estudos de ligação in-vitro e de competição com células MM U266 foram realizados por até 120 minutos. Foram obtidas imagens de microscopia de força fluorescente e atômica de células U266. Estudos in-vivo foram realizados em ratos CD1 normais (n=3). Um PRQ superior a 90% foi observado com ambos os queladores utilizados, sendo estável e não mostrando nenhuma trans-quelação significativa por pelo menos 24 hs. A microscopia confocal mostrou a capacidade da Tocilizumab-FITC de reconhecer IL6R em células U266. As experiências de ligação e deslocamento in-vitro confirmam a especificidade do reconhecimento do 99mTc-Tocilizumab pelo IL6R. Os estudos de biodistribuição mostraram principalmente absorção hepática e eliminação renal. A partir dos resultados obtidos, concluiu-se que tanto o Tocilizumab 99mTco4- rotulado via HYNIC quanto o tricarbonil, poderiam ser potenciais agentes de imagem para o diagnóstico do mieloma múltiplo. Recebido para revisão: junho de 2012.Aceito para publicação: Agosto de 2012.

1 June 2018 in SALUD MILITAR
Verified
Journal Article
Open access
PDF file
LALucía Alfaya
Lucía Alfaya
XCXimena Camacho
Ximena Camacho
MCMirel Cabrera
Mirel Cabrera
María Fernanda GarcíaMaría Fernanda García
María Fernanda García
MFMarcelo Fernández
Marcelo Fernández
PCPablo Cabral
Pablo Cabral
La hormona liberadora de la hormona luteinizante es un decapéptido producido por el hipotálamo y posee un rol fundamental en la regulación del eje pituitario/gonadal y en el ciclo ovárico. Es capaz de unirse a receptores específicos sobre las células gonadales para regular la síntesis y secreción de las hormonas gonadotróficas, las hormonas luteinizante y folículo estimulante. A su vez, se ha comprobado que receptores específicos de la hormona liberadora de la hormona luteinizante se encuentran sobreexpresados en cáncer mama, próstata, ovárico, entre otros; lo cual ha permitido su utilización, tanto de análogos como agonistas, en terapia para estas neoplasias, principalmente en cáncer de próstata y mama. Por lo anterior, nos planteamos desarrollar y optimizar la marcación con el radionucléido emisor gamma, el 99m-Tecnecio, del péptido LHRH, a modo de evaluar su potencial empleo como agente de imagen molecular en oncología. Para esto, el HYNIC-GSG-LHRH fue adquirido comercialmente. La marcación con 99mTc fue realizada a 50 ºC en presencia de diferentes co-ligandos incluyendo Tricina, Ácido etilendiaminodiacético, Tricina/Ácido etilendiaminodiacético y Tricina/Ácido Nicotínico. Las condiciones de marcación (pH, concentración de coligandos, concentración de agente reductor (cloruro de estaño), temperatura y tiempo de reacción) fueron optimizadas en orden, para estandarizar el procedimiento. Se evaluaron las purezas radioquímicas por HPLC. Tanto los coeficientes de partición (Log P) y la estabilidad in vitro fueron determinadas a modo de obtener un agente de imagen estable y de alta pureza radioquímica. Se realizaron estudios biológicos in vitro de afinidad en distintas líneas celulares humanas de mama y próstata (MDA-MB-231, MCF-7 y MDA-MB-435) y próstata (PC3, LnCap y Du-145), así como su perfil de biodistribución en modelos murinos; a modo de obtener una aproximación al comportamiento biológico del nuevo radiotrazador. Logramos marcar el conjugado HYNIC-GSG-LHRHcon 99m-Tecnecio, empleando altas actividades específicas usando como co-ligandos tanto Tricina como la mezcla Tricina/Ácido Nicotínico, obteniendo altas purezas radioquímicas (> 95%), alta estabilidad in vitro y baja lipofilicidad (Log P de -2,5 ± 0,05 y -2,82 ± 0,04, empleando Tricina y Tricina/Ácido Nicotínico, respectivamente). El conjugado [99mTc]-HYNIC-GSG-LHRH/Tricina-Ácido Nicotínico reveló elevada afinidad de unión específica por los receptores de la hormona liberadora de la hormona luteinizante expresados en las líneas celulares de mama y próstata. Se observó que el complejo radiomarcado presenta un perfil de biodistribución óptimo para ser empleado como potencial agente de imagen. Recibido para evaluación: Febrero 2018 Aceptado para publicación: Setiembre 2018 Correspondencia: Laboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay. Mataojo 2055, P.O. 11400, Montevideo, Uruguay. Tel.: (+5982) 5250901/108. Fax: (+5982) 5250895. E-mail de contacto: lalfaya.27@gmail.com Luteinizing hormone-releasing hormone is a decapeptide produced by the hypothalamus and has a fundamental role in the regulation of the pituitary/gonadal axis and in the ovarian cycle. It is able to bind to specific receptors on gonadal cells to regulate the synthesis and secretion of gonadotrophic hormones, luteinizing hormones and follicle stimulating hormones. In turn, it has been shown that specific receptors of the hormone releasing luteinizing hormone are overexpressed in breast, prostate, ovarian cancer, among others; which has allowed its use, both analogues and agonists, in therapy for these neoplasms, mainly in prostate and breast cancer. Therefore, we proposeto develop and optimize the gamma emitting radionuclide labeling, 99m-Technetium, of the LHRH peptide, in order to assess its potential use as a molecular imaging agent in oncology. For this purpose, the HYNIC-GSG-LHRH was purchased commercially. The 99mTc labeling was performed at 50°C in the presence of different co-ligands including Tricine, Ethylenediamine diacetic acid, Tricine/Ethylenediamine diacetic acid and Tricine/Nicotinic acid. The marking conditions (pH, concentration of co-ligands, concentration of the reducing agent (tin chloride), temperature and reaction time) were optimized in order to standardize the procedure. The radiochemical purities were evaluated by HPLC. Both the partition coefficients (Log P) and in vitro stability were determined in order to obtain a stable imaging agent of high radiochemical purity. In vitro biological affinity studies were performed in different human breast and prostate cell lines (MDA-MB-231, MCF7 and MDA-MB-435) and prostate (PC3, LnCap and Du-145), as well as their profile of biodistribution in murine models; in order to obtain an approximation to the biological behavior of the new radiotracer. We managed to label the conjugate HYNIC-GSG-LHRH with 99m-Tecnecio, using high specific activities using as co-ligands both Tricine and the Tricine/Nicotinic Acid mixture, obtaining high radiochemical purities (> 95%), high stability in vitro and low lipophilicity (Log P of -2,5 ± 0,05 and -2,82 ± 0,04, using Tricine and Tricine/Nicotinic Acid, respectively). The [99mTc] -HYNIC-GSG-LHRH/Tricine-Nicotinic Acid conjugate revealed a high specific binding affinity for the luteinizing hormone-releasing hormone receptors expressed in the breast and prostate cell lines. It was observed that the radiolabeled complex presents an optimal biodistribution profile to be used as a potential imaging agent.